ECB Governing Council member Mahfouf: No signs of second-round inflation effects have been observed yet

According to Jinse Finance, early-stage RNAi drug developer City Therapeutics Inc. (CTY.US) is seeking to raise up to 184.7 millions USD in its U.S. initial public offering (IPO). According to documents filed with the U.S. Securities and Exchange Commission on Friday, the company, whose investors include Arch Venture Partners and Fidelity Management & Research, plans to issue 9.72 million shares at a price range of $17 to $19 per share.

Zhihu Finance APP noted that medical device companies are expected to go through another sluggish earnings season before entering 2027 with the strongest growth outlook in more than two years—following a challenging period for the industry marked by policy uncertainty, cyberattacks, and product recalls.

Pakistan's national oil company has signed an oil supply agreement with Oman OQ.

(1) Commerzbank warns that France's debt issues may pose an even greater systemic risk to the eurozone than the Greek sovereign debt crisis. (2) The institution points out that public debt in the eurozone currently averages about 90% of economic output, up from around 80% in 2009. (3) Meanwhile, the willingness of various parties to advance fiscal reforms has weakened. (4) However, a more robust banking system, French institutions, and the intervention tools of the European Central Bank have reduced the likelihood of risk contagion. (5) Commerzbank does not expect a new sovereign debt crisis to occur but warns that related risks are on the rise. (6) On the market front, France's fiscal trajectory and the sustainability of eurozone debt remain potential variables in the pricing of long-term interest rates. (7) Ongoing attention should be paid to the progress of French fiscal reforms and the application of European Central Bank policy tools.